Selected issues in the psychopharmacologic treatment of women with psychiatric disorders

Journal of Practical Psychiatry and Behavioral Health

Volumn 3, Issue 5, 1997, Pages 275-284

  Dubovsky, Steven L ^a,b   Giese, Alexis ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Breast feeding; Menopause; Mood disorders; Pregnancy; Premenstrual dysphoric disorder; Psychopharmacology; Women

Indexed keywords

EID: 33749416017     PISSN: 10765417     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-199709000-00002     Document Type: Article

References (85)

1. th Edition. Baltimore: Williams & Wilkins; 1995.
2. Jensvold MF, Halbreich U, Hamilton JA. Psychopharmacology and women: Sex, gender and hormones. Washington, DC: American Psychiatric Press; 1996.
3. Ashton H. Psychotropic drug prescribing for women. Br J Psychiatry 1991;158:30-5.
4. Zadoronznjy M, Svarstad BL. Gender, employment and medication use. Soc Sci Med 1990;31:971-8.
5. Enorre E, Klakka T, Riska E. Psychotropic drugs: Long-term use, dependency and the gender factor. Soc Sci Med 1994;39:1667-73.
6. Baumann M, Pommier J, Deschamps JP. Medical prescription and consumption of psychotropic drugs: Questions on the differences between men and women. Cahiers de Sociologie et de Demographie Medicales 1996;36:63-78.
7. Halbreich U, Carson SW. Drug studies in women of childbearing age: Ethical and methodological considerations. J Clin Psychopharmacol 1989;9:328-33.
8. Schmucker DL, Vesell ES. Underrepresentation of women in clinical drug trials. Clin Pharmacol Ther 1993;54:11-15.
9. Leibenluft E, Fiero PL, Rubinow DR. Effects of the menstrual cycle on dependent variables in mood disorder research. Arch Gen Psychiatry 1994;51:761-81.
10. Dawkins K, Potter WZ. Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: Focus on women. Psychopharmacol Bull 1991;27:417-23.
11. Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. Adolesc Health 1989;9:328-33.
12. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992;149:587-95.
13. Kashuba ADM, Shirey CS, Bertino JS, Nafzinger AN. Effect of menstrual cycle (MC) phase on CYP2D6 activity in extensive metabolizers (EMs) as measured by dextromethorphan phenotyping. Clin Pharmacol Ther 1997;226:23-26.
14. Leibenluft E. Women with bipolar illness: Clinical and research issues. Am J Psychiatry 1996;153:163-73.
15. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992;11:851-6.
16. Reicher-Rossler A, Hafner H. Schizophrenia and oestrogens - is there an association? Eur Arch Psychiatry Clin Neurosci 1993;242:323-8.
17. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla W. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
18. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla W. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
19. Mehtonen OP, Malkonen L, Vapaatalo H. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991;84:58-64.
20. Glassman A, Proud'homme X. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993;54(suppl 2):16-22.
21. Thorogood M, Cowen PJ, Mann JJ. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1992;340:1067-88.
22. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Study. Arch Gen Psychiatry 1994;51:8-19.
23. Pearlstein TB. Hormones and depression: What are the facts about premenstrual syndrome, menopause and hormone replacement therapy? Am J Obstet Gynecol 1995;173:646-53.
24. Pariser SF. Women and mood disorders: Menarche to menopause. Annals of Clinical Psychiatry 1993;5:249-54.
25. Parry BL, Rausch JL. Premenstrual dysphoric disorder. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry, 6th ed. Baltimore: Williams and Wilkins; 1995:1701-13.
26. DeMonico SO, Brown CS, Ling FW. Premenstrual syndrome. Current Opinion in Obstetrics & Gynecology 1994;6:499-502.
27. Budeiri DJ, Li wan Po A, Dornan JC. Clinical trials of treatments of premenstrual syndrome: Entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynecol 1994;101:689-95.
28. Rausch JL, Parry BL. Treatment of premenstrual mood syndromes. Psychiatr Clin N Am 1991;16:829-39.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association; 1994.
30. Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS. Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, crossover study. Obstet Gynecol 1992;80(3 Pt 1):339-44.
31. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo-controlled trial. Neuropsychopharmacology 1993;9:133-45.
32. Rickels K, Freeman E, Sondheimer S, Albert J. Fluoxetine in the treatment of premenstrual syndrome. Curr Ther Res 1990;48:161-7.
33. Steiner W, Steinberg S, Stewart DE, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529-34.
34. Menkes DB, Taghavi E, Mason PA, Howard RC. Fluoxetine's spectrum of action in premenstrual syndrome. Int Clin Psychopharmacol 1993;8:95-102.
35. Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994;55:332-5.
36. Yonkers KA, Halbreich U, Freeman E, Brown CS, Pearlstein TB. Sertraline in the treatment of premenstrual dysphroic disorder. Psychopharmacol Bull 1996;32:41-6.
37. Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: A placebo-controlled trial. Acta Psychiatr Scand 1992;85:39-47.
38. Freeman E, Rickels K, Sondheimer S, Wittmaack FM. Sertraline versus desipramine in the treatment of premenstrual syndrome: An open-label trial. J Clin Psychiatry 1996;57:7-11.
39. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-76.
40. Freeman E, Rickels K, Sondheimer S. Fluvoxamine for premenstrual dysphoric disorder: A pilot study. J Clin Psychiatry 1996;57 Suppl 8:56-9.
41. Taghavi E, Menkes DB, Howard RC, Mason PA, Shaw JP, Spears GF. Premenstrual syndrome: A double-blind controlled trial of desipramine and methylscopolamine. Int Clin Psychopharmacol 1995;10:119-22.
42. Parry BL, Mahan AM, Mostofi N, Klauber MR, Lew GS, Gillin JC. Light therapy of late luteal phase dysphoric disorder: An extended study. Am J Psychiatry 1993;150:1417-19.
43. Giannini AJ, Sullivan B, Sarachene J, Loiselle RH. Clonidine in the treatment of premenstrual syndrome: A subgroup study. J Clin Psychiatry 1988;49:62-3.
44. Brzezinski AA, Wurtman JJ, Wurtman RJ, Gleason R, Greenfield J, Nader T. d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Pa Med 1990;76:296-301.
45. Meden-Vrtovec H, Vujic D. Bromocriptine (Bromergon, Lek) in the management of premenstrual syndrome. Clin Exper Obstet Gynecol 1992;19:242-8.
46. Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: A double-blind, placebo-controlled study. Acta Obstetrica et Gynecologica Scandanavia 1995;74:803-8.
47. Goei GS, Abraham GE. Effect of a nutritional supplement, optivite, on symptoms of premenstrual tension. J Reprod Med 1983;28:527-33.
48. London RS, Bradley L, Chiamori NY. Effect of a nutritional supplement on premenstrual symptomatology in women with premenstrual syndrome: A double-blind longitudinal study. J Am Coll Nutrition 1991;10:494-9.
49. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. Arch Gen Psychiatry 1990;47:270-5.
50. Freeman E, Rickels K, Sondheimer S, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995;274:51-7.
51. Tsuang MT, Faraone SV. The inheritance of mood disorders. In: Hall LL, ed. Genetics and mental illness: Evolving issues for research and society. New York: Plenum; 1996:79-109.
52. Berrettini WH, Ferraro TN, Goldin LR, et al. A linkage study of bipolar illness. Arch Gen Psychiatry 1997;54:27-35.
53. Gershon ES. Genetics. In: Goodwin FK, Jamison KR, eds. Manic-depressive illness. New York: Oxford University Press; 1990:373-101.
54. Kendler K. Toward a scientific psychiatric nosology. Arch Gen Psychiatry 1990;47:969-73.
55. Kendler KK, Neale MC, Kessler RC, Heath AC, Eaves LJ. Major depression and generalized anxiety disorder: Same genes, (partly) different environments? Arch Gen Psychiatry 1992;49:716-22.
56. Post RM. Mechanisms underlying the evolution of affective disorders: Implications for long-term treatment. In: Grunhaus L, Greden JP, eds. Severe Depression Disorders. Washington, DC: American Psychiatric Press Inc.; 1994:23-65.
57. Kendler KK, Kessler CC, Neale MC, Heath AC, Eaves L.J. The prediction of major depression in women: Toward an integrated etiologic model. Am J Psychiatry 1993;150:1139-48.
58. Dubovsky SL. Mind-body deceptions. New York: W.W. Norton; 1997.
59. Leibenluft E, Clark CH., Myers FS. The reproducibility of depressive and hypomanic symptoms across repeated episodes in patients with rapid-cycling bipolar disorder. Journal of Affective Disorders 1995;33:83-8.
60. Goodwin FK, Jamison KR. Manic depressive illness. New York: Oxford University Press; 1991.
61. Brown S, Steinberg RL, van Praag HM. The pathogenesis of depression: Reconsideration of neurotransmitter data. In: den Boer JA, Sitsen JMA, eds. Handbook of depression and anxiety. New York: Marcel Dekker; 1994:317-47.
62. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999-1010.
63. Devanand DP, Sackeim HA, Lo E-S, et al. Serial dexamethasone suppression tests and plasma dexamethasone levels. Arch Gen Psychiatry 1991;48:525-33.
64. Kuller JA, Katz VL, McMahon MJ, Wells SR, Bashford RA. Pharmacologic treatment of psychiatric disease in pregnancy and lactation: Fetal and neonatal effects. Obstet Gynecol 1996;87(5 Pt 1):789-98.
65. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin MJ, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry 1996;153:592-606.
66. Walker R, Swartz CM. Electroconvulsive therapy during high-risk pregnancy. Gen Hosp Psychiatry 1994;16:348-53.
67. Hartz SC, Heinonen OP, Shapiro S. Antenatal exposure to meprobamate and chlordiazepozide in relation to malformations, mental development and childhood mortality. N Engl J Med 1975;292:726-8.
68. Auerbach JG, Hans SL, Marcus J, Maier S. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol 1992;14:399-406.
69. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336: 258-62.
70. Bologna M, Tang B, Klein J. Pregnancy-induced changes in drug metabolism in epileptic women. J Pharmacol Exper Ther 1991;257:736-40.
71. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993;150:1541-2.
72. Yonkers KA, Kando JC, Hamilton JA. Gender issues in psychopharmacologic treatment. Essential Psychopharmacology 1996;1:54-66.
73. Backstrom T. Symptoms related to the menopause and sex steroid treatments. Ciba Foundation Symposium 1995;191:171-80.
74. Coope J. Hormonal and non-hormonal interventions for menopausal symptoms. Maturitas 1996;23:159-68.
75. Kaufert PA, Gilbert P, Tate R. The Manitoba Project: A re-examination of the link between menopause and depression. Maturitas 1992;14:143-55.
76. Breckwoldt M, Keck C, Karck U. Benefits and risks of hormone replacement therapy. Journal of Steroid Biochemistry and Molecular Biology 1995;53:205-8.
77. Hammond CB. Menopause and hormone replacement therapy: An overview. Obstet Gynecol 1996;87(2 Suppl):2S-15S.
78. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiology 1994;140:256-61.
79. Ewerttz M. Hormone therapy in the menopause and breast cancer risk - a review. Maturitas 1996;23:241-6.
80. Colditz GA. The use of estrogen and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332: 1589-93.
81. Jones KP. Estrogens and progestins: What to use and how to use it. Clin Exper Obstet Gynecol 1992;35:871-83.
82. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71.
83. Soffa VM. Alternatives to hormone replacement for menopause. Alternative Therapies in Health and Medicine 1996;2:34-9.
84. Montgomery JC, Appleby L, Brincat M, et al. Effect of estrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987;1:297-9.
85. Limouzin-Lamothe MA, Mairon N, Joyce CRB, Le Gal M. Quality of life after the menopause: Influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170:618-24.